糖尿病视网膜病变患者白内障手术中应用抗血管内皮生长因子药物的研究进展  

Research progress of anti-vascular endothelial growth factor in cataract surgery for diabetic retinopathy

作　　者：张琪 谢达森 李永浩[1] Zhang Qi;Xie Dasen;Li Yonghao(State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center,Sun Yat-sen University,Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science,Guangdong Provincial Clinical Research Center for Ocular Diseases,Guangzhou 510060,China)

机构地区：[1]中山大学中山眼科中心,眼科学国家重点实验室,广东省眼科视觉科学重点实验室,广东省眼部疾病临床医学研究中心,广州510060

出　　处：《中华眼底病杂志》2022年第1期72-76,共5页Chinese Journal of Ocular Fundus Diseases

基　　金：广东省自然科学基金(2017A030313455)。

摘　　要：糖尿病视网膜病变(DR)是糖尿病患者的常见眼部并发症,呈慢性、进行性发展,严重损害患者视力;而糖尿病患者的白内障发生及进展较快,也是引起DR患者视力损害的重要原因之一。与非糖尿病患者相比,糖尿病患者在白内障手术后发生并发症的风险也更高。研究证实,伴有糖尿病黄斑水肿的DR患者白内障手术中使用抗血管内皮生长因子(VEGF)药物治疗可预防其手术后病变加重。但由于目前国内缺乏系统性回顾分析抗VEGF药物在DR患者白内障手术中的临床效果,临床上对于抗VEGF药物的使用相对保守。相信随着各项研究的深入和临床试验的进展,抗VEGF药物在临床的广泛应用指日可待,未来有望为DR患者提供更精准有效的治疗。Diabetic retinopathy(DR)is a common ocular complication in diabetic patients,which is chronic and progressive and seriously impairs visual acuity.The rapid occurrence and progress of cataract in diabetic patients is also one of the important reasons for visual impairment in DR patients.Compared with non-diabetic patients,diabetic patients have higher risk of complications after cataract surgery.Studies have shown that anti-vascular endothelial growth factor(VEGF)therapy after cataract surgery can prevent the aggravation of diabetic macular edema in DR patients.However,due to the lack of systematic review of the clinical effect of anti-VEGF drugs in DR patients undergoing cataract surgery,the use of anti-VEGF drugs is relatively conservative in clinic.It is believed that with the deepening of research and the progress of clinical trials,the wide application of anti-VEGF drugs in clinical practice is expected to provide more accurate and effective treatment for DR patients in the future.

关 键 词：糖尿病视网膜病变 白内障摘除术 血管生成抑制剂 综述 

分 类 号：R779.6[医药卫生—眼科] R587.2[医药卫生—临床医学]